drugset / Trial / NCT01629225

GRK4 Polymorphisms Blood Pressure Response to Candesartan

NCT01629225

Phase 4 Unknown 500 enrolled Third Military Medical University
NaSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Timeline

Start
2013-07
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Candesartan Unknown 10 mg
Comparator Candesartan Unknown 20 mg